HP-Mediated Reduction of polyQ Aggregates Depends on PERK Signaling and Autophagy
(A) WT N2a cells transiently expressing the C-terminal ATX3 fragment described in Figure 2A were treated with the indicated compounds (10 mM GlcNAc, 160 nM BafA, 10 nM PERK inhibitor GSK2606414) and processed for fractionation and western blotting. * Partially formic acid soluble material; 1, endogenous ATX3; 2, exogenous ATX3 fragment.
(B) WT and GFAT1 G451E N2a cells transiently expressing the C-terminal ATX3 fragment as described in Figure 2C were treated with the indicated compounds (160 nM BafA, 10 nM PERK inhibitor GSK2606414) and processed for fractionation and western blotting.
See also Figure S3.